RxDoctor Payments Data

Douglas Wu

San Diego, CANPI 1861874885

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $105,500 of the $163,405 with a category attached, or 64.6%. Galderma Laboratories, L.p. accounts for 70.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $98,706 and has fallen 81.2% since, to $18,527 in 2025.

$163,405in general payments, 2019–2025

Across 160 payments — averaging $1021.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$115K
  • AbbVie$30K
  • Solta Medical, A Division Of Bausch Health US, LLC$18K
  • Revance Therapeutics, Inc.$55
  • Biofrontera Inc.$24
  • Merz North America, Inc.$21
$1,000in research payments, 2019–2025

Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Galderma Laboratories, L.p.$1K

What the payments were for

  • Consulting fees$47,11629%
  • Speaking & faculty fees$105,50065%
  • Travel & lodging$8,1385%
  • Food & beverage$2,6522%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →